Vast Fields of Biologically Active Chemical Space

Key Takeaways

• In‑stock library hits were more “bio‑like” but not more selective.
• Make‑on‑demand library screened 1.6 billion compounds, 384 tested.
• Hit rate ~24% for both libraries against 5‑HT2AR.
• Promiscuity across 318 GPCRs differed only marginally (1.7% vs 2.1%).
• Study suggests vast, non‑bio‑like chemical space is biologically active.

Pulse Analysis

The concept of a narrow, biologically relevant chemical niche has long guided library design, with early fragment‑based programs favoring structures reminiscent of metabolites or natural products. Over the past decade, commercial make‑on‑demand (MoD) collections have exploded, offering billions of synthetically accessible molecules that diverge sharply from traditional “bio‑like” scaffolds. This shift raises a critical question for medicinal chemists: does expanding into uncharted chemical territory dilute the probability of finding functional hits, or does it simply illuminate a broader, untapped landscape?

In the recent J. Med. Chem. investigation, researchers at UCSF and UNC screened both a massive 1.6 billion‑compound MoD set and a modest 3.5 million‑compound in‑stock set against the 5‑HT2A receptor using DOCK3.8. From the top‑scoring candidates, 85 in‑stock and 384 MoD molecules were experimentally evaluated, yielding nearly identical hit rates of roughly 24%. Functional profiling revealed a balanced mix of agonists and antagonists, and a comprehensive GPCR panel showed only a slight increase in off‑target binding for MoD hits (2.1% versus 1.7%). These data suggest that chemical novelty does not inherently compromise target engagement or selectivity.

For the drug‑discovery industry, the implications are profound. The comparable performance of ultra‑large, non‑bio‑like libraries means that companies can confidently invest in expansive virtual screens without fearing a surge in promiscuous liabilities. Moreover, the findings encourage a re‑evaluation of library curation strategies, emphasizing diversity and synthetic accessibility over strict adherence to natural‑product‑like motifs. As computational power and docking algorithms continue to improve, the frontier of chemically active space is likely to expand even further, offering fresh opportunities for innovative therapeutics across a range of disease targets.